View More Recent Stories
-
TD Cowen Reiterates Buy Rating on Arrowhead Pharma (ARWR)
-
Arrowhead Pharmaceuticals Inc. (ARWR) to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
-
Piper Sandler Reiterates Overweight Rating on Arrowhead Pharma (ARWR)
-
Arrowhead Pharmaceuticals Inc. (ARWR) to Advance ARO-INHBE and ARO-ALK7 Into Clinical Studies
-
Arrowhead Pharmaceuticals Inc. (ARWR) Misses Q3 EPS by 85c
-
Arrowhead Pharmaceuticals (ARWR) Announces $500 Million Strategic Financing Facility with Sixth Street
-
Arrowhead Pharma (ARWR) PT Lowered to $60 at H.C. Wainwright
-
TD Cowen Reiterates Buy Rating on Arrowhead Pharma (ARWR)
-
Arrowhead Pharmaceuticals (ARWR) to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial
-
Arrowhead Pharmaceuticals Inc. (ARWR) Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE
